Insilico Medicine launches personalized drug discovery platform to develop new treatments for ALS

Today, Insilico Medicine, Inc., a company applying the latest advances in deep learning to biomarker development, drug discovery and aging research, launched ALS.AI, a personalized drug discovery and biomarker development platform utilizing the latest advances in deep learning.

About the author

Samuel Nelson

View all posts

Leave a Reply

Your email address will not be published. Required fields are marked *